




A FLEXIBLE APPROACH TO VACCINE CLINICAL TRIALS

WHEN YOUR FOCUS IS CLINICAL TRIALS, QPS' global clinic network provides the ideal support for your Phase I - IV clinical trials from initiation through filing.



THE NEED FOR VACCINES

According to the WHO, there is no single preventative health intervention more cost effective than immunization. In fact immunization prevents 2 - 3 million deaths every year. In 73 low and middle income countries, vaccines given between 2001 and 2020 will avert 20 million deaths, while saving \$350 billion in costs of illness and \$5 billion in healthcare costs (Ozawa et al., 2017).

CURRENT CHALLENGES

While no one denies the significant need that exists for new vaccines, there is a long list of challenges that stand in the way of their development. The need is greatest in developing countries where the ability to pay for vaccines is at its lowest level, reducing the commercial incentive required to offset years of development costing millions of dollars.

In addition, many of the diseases that are the most troublesome in these countries are tropical diseases affecting small populations, but those effects have a huge economic impact, in some cases perpetuating the cycle of poverty due to lifelong debilitating health effects of the disease.

QPS VACCINE DEVELOPMENT EXPERIENCE

QPS has extensive vaccine experience, having conducted over 200 Phase I - IV studies, including First in Human studies, conducted in the United States, Asia and Europe. This experience covers a broad range of vaccine indications including, but not limited to, Anthrax, Clostridium difficile, Ebola, E. Coli, Flu, Hepatitis B, Herpes, HIV, HPV, Norovirus, Meningitis, Plague, Pneumonia, RSV, Zika, etc., across almost every possible route of administration including Oral, Intranasal, Transdermal, Intramuscular, Subcutaneous, and Intradermal.

STUDY PARTICIPANTS

QPS provides a unique approach that enables rapid completion of enrollment at one or more of our three global Phase I sites. We realize that subjects who typically participate in trials with confinement are not the same subjects who will participate in outpatient trials, such as vaccine trials. Armed with this knowledge, QPS has the ability to fill over 80% of trials exclusively from the database, with an average dropout rate of less than 5%. This very low drop out rate is even accomplished in long term vaccine trials.

EXPERIENCED INVESTIGATORS

QPS has developed significant relationships with a wide range of investigators across a broad range specialties and sub-specialties. These relationships provide strong foundations for ensuring quality studies are performed. We take pride in the fact that we can utilize the skills of the most experienced investigators for every clinical trial conducted by QPS. These investigators are supported by ACRP certified coordinators to ensure that every trial has the best chance of success.

QPS FOR YOUR NEXT VACCINE TRIAL

Through a dedicated framework of integrated vaccine research clinics and investigators, QPS offers a full range of outsourcing solutions. Whether your vaccine is for a tropical disease, or a novel treatment for cancer, QPS has the experience and resources to handle your drug development program and help to get your vaccine to market.





QPS IS A GLOBAL CRO WITH LOCATIONS AROUND THE WORLD

BENEFIT FROM THE RESOURCES OF A GLOBAL CRO



Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy or cell therapy, QPS provides a full range of clinical trial services to support drug development needs from discovery, through clinical development and regulatory filing.



CUSTOM-BUILT RESEARCH™

**TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT
TEAM TODAY!**

Call +1 512 350 2827

Email infobd@qps.com

